nlwxpearo
Joined: 13 Dec 2010
Posts: 520
Read: 0 topics
Warns: 0/5
Location: England
|
 Posted: Sun 20:22, 20 Mar 2011 Post subject: Lipid-lowering drugs statins Research and market p |
|
|
Lipid-lowering drugs statins Research and market prospects (a)
Coronary Atherosclerosis Study (LCAS) has been concluded. IDI 429 cases with a high coronary artery disease hyperlipidemia C (age 35 to 75 years old,[link widoczny dla zalogowanych], female 81 cases) application of fluvastatin or placebo orally 1 20mg, 1 day 2 times; of which about 259 / 5, plasma LDL- C ≥ 160mg/dl,[link widoczny dla zalogowanych], high-risk patients and 1 day with cholestyramine 12g adjuvant therapy, continuous 32 months. In the treatment of early and terminal, with coronary angiography and the ) change,[link widoczny dla zalogowanych], to assess the anti-fluvastatin effect of atherosclerosis. Treatment outcome,[link widoczny dla zalogowanych], all patients taking this LDL-C decreased 23.9o / 4 (reduced by the 146mg/dl 11lmg/d1),[link widoczny dla zalogowanych], compared with placebo, patients taking this significantly shorten the process of coronary artery injury, MLD were 0.028mm and 0.100mm (P <0.01). In addition, FLARE test confirmed that fluvastatin to reduce PT-CA patients after myocardial infarction incidence and mortality, the current prevention of fluvastatin role in restenosis after PTCA experiments are under way. 2.4 hyperlipidemia secondary to diabetes, foreign reports, Knopp and other random, double-blind, placebo-controlled, application of fluvastatin treatment of 66 patients with type Ⅱ diabetes-induced hyperlipidemia secondary to the patient by a days of 20mg or 40mg, 1 night, for 9 to 12 weeks, TC decreased 19.9, LDL-C decreased 24.3o / 4 (P <0.001), TG decreased 15.3 (P <0. 01), HDL-C increased 4.6 (P <0.05), LDL-C/HDI a C ratio decreased 26.1 (P <0.001), fluvastatin treatment did not cause abnormal blood glucose control . Preliminary results confirm that fluvastatin induced type Ⅱ diabetes and LDL-C in patients with elevated TG safe and effective. (Continued) fire with fire bear fruit - As market conditions preparation of progress and Zhang Lun (Nanjing Pharmaceutical Factory 210002) Arsenic trioxide (AS. O) commonly known as arsenic, a toxic compound. In recent years, scientists have to start from the folklore remedies, developed a preparation of arsenic, which in the treatment of leukemia in a major breakthrough, the scientific community caused concern home and abroad, and its market prospects are very promising. 1. Progress in clinical studies of acute promyelocytic leukemia is a dangerous disease. Years ago, the primary means of clinical disease is the use of cytotoxic chemotherapy, but the effect is not ideal. Overall, only cured with chemotherapy alone in patients 35 to 45, and very easy to relapse. In 1986, people began to use all-trans retinoic acid treatment of the disease. All-trans retinoic acid than by cytotoxicity, but the cells induced differentiation of lesions that gradually replace the normal polyclonal hematopoietic leukemia hematopoietic sick. Clinical studies have shown that all-trans retinoic acid can make 80% to 90% of acute promyelocytic leukemia complete remission. However, the drug also inadequate, first, 1 / 2 to 1 / 3 of patients will rapidly increase in white blood cells, white blood cells to produce high viremia. Secondly, the patient will develop resistance and lead to relapse. Later, people in the mining and from the treasures of traditional medicine. Early in the 20th century, 70's, Affiliated Hospital of Harbin Medical University, an expert on the use of civil remedies to collect, with arsenic (arsenic trioxide) in the treatment of leukemia achieve better results. Later developed arsenic trioxide injection. In 1996, Harbin Medical University, preparation pure arsenic trioxide treatment of 30 patients with acute promyelocytic leukemia relapse onset and 42 patients with clinical complete remission rate was 73.3 and 52.0%. In the same year, the Shanghai Institute of Hematology 16 patients reported recurrence of patients, clinical complete remission rate was 93.7%. Then the domestic larger clinical studies confirm the efficacy of arsenic trioxide. At the same time, the Shanghai Institute of Hematology, Wang Zhenyi, researchers led by Chen Zhu and other academicians in-depth study of molecular oncology from the perspective reveals the preparation of arsenic treatment in acute promyelocytic leukemia mechanism, namely through the degradation of PML / RARa fusion protein, decreased Bcl2 gene expression, induce apoptosis of leukemia cells for therapeutic purposes. The study results will fight like the simple of traditional medicine knowledge elevated to a high degree of genetic theory, so that the world's first arsenic preparation apoptosis induction. Preparations used in the treatment with arsenic trioxide is the amount of
The post has been approved 0 times
|
|
